Kodiak Says Zenkuda Met Its DAYBREAK Primary Endpoint at p=0.0007 With 54% of Patients on Six-Month Dosing. Its Last 10-Q Carried a Going-Concern Warning and $125.9 Million of Cash.

by Carter Whitfield · September 30, 2026

Equities Reporter, The SmallCap Signal

Kodiak Sciences said on Sept. 28 that both investigational arms of its Phase 3 DAYBREAK study in wet age-related macular degeneration met their primary endpoints against the active comparator aflibercept. Zenkuda (tarcocimab tedromer) met the one-year non-inferiority endpoint on best corrected visual acuity with a p-value of 0.0007, and 54% of Zenkuda patients were on a six-month dosing interval at year one under what the company calls strict treat-to-dryness retreatment criteria, according to the press release filed as an exhibit to an 8-K the same day.

The second arm, tabirafusp alfa tedromer (KSI-501), a bispecific anti-IL-6 and VEGF-trap conjugate, met the vision primary endpoint with a p-value of 0.0036 and its anatomical key secondary endpoint with a p-value below 0.0001, the release says. Kodiak describes DAYBREAK as a non-inferiority study evaluating parallel arms of the two candidates against aflibercept dosed per label, and says both achieved non-inferiority in vision gains at year one.

What the release does not give is the number of letters gained on either arm, the non-inferiority margin, or the size of the treated population. It states p-values and the proportion of patients reaching a 24-week interval, and says detailed results would be presented on a company webcast at 8:30 a.m. ET on Sept. 28. Readers looking for the mean BCVA change from baseline, the primary measure in the trial's design, will need the presentation or a later publication.

On safety, the company reported a 0% intraocular inflammation rate and a 0.5% cataract adverse event rate for Zenkuda, against 0.9% cataract events in the aflibercept comparator, and a 0.4% intraocular inflammation rate and 0% cataract rate for tabirafusp-ted, according to the release. Both were described as consistent with the established safety profile of aflibercept.

The dosing design matters because durability is the product's pitch. Patients randomized to Zenkuda received four monthly loading doses and were then dosed on an individualized basis every four to 24 weeks, with retreatment triggered by any detectable retinal fluid on OCT rather than by a combination of central subfield thickness and vision loss, the release says. Tabirafusp-ted patients received fixed every-eight-week dosing with additional as-needed dosing up to monthly after four loading doses. The primary endpoint for the KSI-501 arm was non-inferiority in change in visual acuity from baseline to the average of Weeks 40, 44 and 48.

Kodiak plans to submit a three-indication biologics license application for Zenkuda in the fourth quarter of 2026, covering wet AMD, diabetic retinopathy and macular edema following retinal vein occlusion, drawing on what it counts as five positive Phase 3 studies: DAYBREAK and DAYLIGHT in wet AMD, GLOW1 and GLOW2 in diabetic retinopathy, and BEACON in RVO, according to the release.

The path to this readout was not straight. "Four years and seven months after our first Phase 3 readout, Zenkuda's profile has come fully into focus through rigorous science, disciplined learning and thoughtful execution," Chief Medical Officer J. Pablo Velazquez-Martin said in the release. Charles Wykoff of Retina Consultants of Texas, quoted in the same document, said Kodiak "persevered through real challenges with the tarcocimab development program, incorporating multiple lessons learned, culminating in a successful DAYBREAK trial."

Kodiak is a Palo Alto, California, precommercial retina company built around an antibody biopolymer conjugate platform it calls ABC, which it says gives Zenkuda a mean ocular half-life of about 20 days in humans, roughly three times that of approved anti-VEGF therapies. It has never generated product revenue. For the quarter ended June 30, 2026, it reported a net loss of $65.6 million, up from $54.3 million a year earlier, and a six-month net loss of $123.8 million, according to its 10-Q filed Aug. 13. Weighted-average shares outstanding in the quarter were 62,628,596.

That 10-Q is the document to read alongside the trial release. Kodiak reported cash and cash equivalents of $125.9 million at June 30, 2026, down from $209.9 million at Dec. 31, 2025, and an accumulated deficit of $1.7 billion. In the liquidity section it wrote that it believes current cash "will be sufficient to support our current and planned operations into 2027 but may not be sufficient to meet our anticipated operating and capital expenditure requirements for the 12 months following the date of this Quarterly Report." The notes state plainly: "As a result, there is substantial doubt regarding the Company's ability to continue as a going concern."

The company has funded itself primarily through common stock issuance and the sale of future royalties, the 10-Q says; the balance sheet carries a $100.0 million liability related to the sale of future royalties, which the filing's fair-value note ties to royalties expected to be paid to Baker Bros. Advisors, LP. It said it plans to raise additional capital and that stockholders would experience dilution from any equity raise. Through Sept. 30, the SEC's filing index showed no prospectus supplement or 8-K for a securities offering since the data release. It did show the other side of the trade: Baker Bros. Advisors, whose managing member Felix J. Baker sits on Kodiak's board, filed a Schedule 13D amendment on Sept. 30 reporting that its funds bought common stock in the open market on Sept. 28 and Sept. 29, at weighted-average prices ranging from $61.21 to $89.86 a share per the transaction exhibit, taking the group's beneficial ownership to 35.0% of the class. By our tally of the exhibit's rows, the Sept. 28 purchases total 1,908,029 shares and the Sept. 29 purchases 33,726.

Shares rose sharply in Monday trading following the announcement, according to a GuruFocus report published Sept. 28, which did not give a closing price. We have not stated a close for Sept. 28 or Sept. 29 because we did not open a page showing one.

Two more readouts are on the calendar. Kodiak said it remains on track to announce topline data in December 2026 for KSI-101 in the Phase 3 PEAK study in macular edema secondary to inflammation, where the candidate is being tested for superiority against sham, and plans a BLA for KSI-101 in the second quarter of 2027. Tabirafusp-ted has moved into the Phase 3 ALTO study in diabetic macular edema, which the release describes as enrolling approximately 910 patients randomized 5:3:5 across two tabirafusp-ted regimens and aflibercept, with a primary endpoint of mean BCVA change from baseline to the average of Weeks 48 and 52.

The company also said post-hoc analyses are planned to identify which treatment-naive wet AMD subgroups may benefit from IL-6 inhibition. The release does not say whether tabirafusp-ted separated from aflibercept on efficacy in the broad population; the planned subgroup work is the closest it comes to addressing that. Its forward-looking statements list, among other risks, that the completed Phase 3 studies may not be sufficient to support a BLA submission or approval in DR, RVO or wet AMD.

What is next: the fourth-quarter BLA filing, the December PEAK readout, and a financing decision the 10-Q says is coming. What is not yet known: the letter-gain numbers and non-inferiority margin behind the p-values, how many patients were in each DAYBREAK arm, the FDA's view of a retreatment regimen the company itself calls individualized, and whether Kodiak uses the post-data share price to raise the capital its own going-concern disclosure says it needs.